Evidence map›Paper›PMID 39204035›Full record

ArticleVaccines2024

Clinical Features and Vaccination Effects among Children with Post-Acute Sequelae of COVID-19 in Taiwan.

Yu-Lung Hsu, Pei-Chi Chen, Yi-Fen Tsai, Chi-Hung Wei, Lawrence Shi-Hsin Wu, Kai-Sheng Hsieh, Miao-Hsi Hsieh, Huan-Cheng Lai, Chien-Heng Lin, Hsiao-Chuan Lin and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yu-Lung HsuDivision of Pediatric Infectious Diseases, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.ORCID 0000-0002-3010-2767
Pei-Chi ChenCenter of Allergy, Immunology and Microbiome (A.I.M), China Medical University Hospital, China Medical University Children's Hospital, Taichung 40447, Taiwan.ORCID 0000-0002-6035-042X
Yi-Fen TsaiInstitute of Population Health Sciences, National Health Research Institutes, Zhunan 350401, Taiwan.
Chi-Hung WeiDivision of Medical Research, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.ORCID 0009-0004-6562-9704
Lawrence Shi-Hsin WuGraduate Institute of Biomedical Sciences, China Medical University, Taichung 40447, Taiwan.
Kai-Sheng HsiehDivision of Medical Research, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
Miao-Hsi HsiehCenter of Allergy, Immunology and Microbiome (A.I.M), China Medical University Hospital, China Medical University Children's Hospital, Taichung 40447, Taiwan.
Huan-Cheng LaiDivision of Pediatric Infectious Diseases, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
Chien-Heng LinDivision of Pediatric Pulmonology and Intensive Care, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
Hsiao-Chuan LinDivision of Pediatric Infectious Diseases, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
Chieh-Ho ChenDivision of Pediatric Pulmonology and Intensive Care, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.ORCID 0000-0003-4486-7469
An-Chyi ChenDivision of Pediatric Gastroenterology, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
Hung-Chih LinDivision of Neonatology, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
I-Ching ChouDivision of Pediatric Neurology, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
Wen-Jue SoongDivision of Pediatric Pulmonology and Intensive Care, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
Kao-Pin HwangDivision of Pediatric Infectious Diseases, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
Henry Horng-Shing LuInstitute of Statistics, National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan.ORCID 0000-0002-4392-3361
Ruby PawankarDepartment of Pediatrics, Nippon Medical School, Tokyo 8602, Japan.
Hui-Ju TsaiInstitute of Population Health Sciences, National Health Research Institutes, Zhunan 350401, Taiwan.ORCID 0000-0002-5338-6117
Jiu-Yao WangCenter of Allergy, Immunology and Microbiome (A.I.M), China Medical University Hospital, China Medical University Children's Hospital, Taichung 40447, Taiwan.ORCID 0000-0003-4540-9822

Funding

An-Nan Hospital, China Medical University, Tainan, Taiwan ANHRF111-03China Medical University Hospital, Taichung, Taiwan C1110831002-6China Medical University Hospital, Taichung, Taiwan DMR-112-043China Medical University Hospital, Taichung, Taiwan DMR-112-047China Medical University Hospital, Taichung, Taiwan DMR-112-052
6 · The paper itself

Abstract

backgroundPost-acute sequelae of SARS-CoV-2 infection (PASC) affects patients after recovering from acute coronavirus disease 2019 (COVID-19). This study investigates the impact of SARS-CoV-2 vaccination on PASC symptoms in children in Taiwan during the Omicron pandemic.

methodsWe enrolled children under 18 years with PASC symptoms persisting for more than 4 weeks. Data collected included demographics, clinical information, vaccination status, and symptom persistence. We used logistic regression models to compare symptoms in the acute and post-COVID-19 phases and to assess the association between vaccination and these symptoms.

resultsAmong 500 PASC children, 292 (58.4%) were vaccinated, 282 (52.8%) were male, and the mean (SD) age was 7.6 (4.6) years. Vaccinated individuals exhibited higher odds of experiencing symptoms in the previous acute phase, such as cough (adjusted odds ratio [AOR] = 1.57; 95% confidence interval [CI]: 1.02-2.42), rhinorrhea/nasal congestion (AOR = 1.74; 95% CI: 1.13-2.67), sneezing (AOR = 1.68; 95% CI: 1.02-2.76), sputum production (AOR = 1.91; 95% CI: 1.15-3.19), headache/dizziness (AOR = 1.73; 95% CI: 1.04-2.87), and muscle soreness (AOR = 2.33; 95% CI: 1.13-4.80). In contrast, there were lower odds of experiencing abdominal pain (AOR = 0.49; 95% CI: 0.25-0.94) and diarrhea (AOR = 0.37; 95% CI: 0.17-0.78) in children who had received vaccination during the post-COVID-19 phase.

conclusionsThis study revealed clinical features and vaccination effects in PASC children in Taiwan. Vaccination may reduce some gastrointestinal symptoms in the post-COVID-19 phase.

Indexed as

childrenCOVID-19post-acute sequelae of SARS-CoV-2 infectionSARS-CoV-2vaccination

Identifiers

PMID39204035
PMCPMC11359259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.